Compendium of Cancer Genome Aberrations

Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 09:41, 2 July 2023

1,011 bytes added ,  09:41, 2 July 2023
no edit summary
Line 1,514: Line 1,514:  
|
 
|
 
|
 
|
−
| ||Snehal Patel (SP)
+
| ||Sumi Kitahara (SK)
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don
 
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don
Line 1,522: Line 1,522:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
 
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
Line 1,530: Line 1,530:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
 
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
Line 1,538: Line 1,538:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
 
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
Line 1,546: Line 1,546:  
|
 
|
 
|?PENDING
 
|?PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
 
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
Line 1,554: Line 1,554:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
 
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
Line 1,562: Line 1,562:  
|
 
|
 
|Complete
 
|Complete
−
|11/21/2021||SP
+
|11/21/2021||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
 
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
Line 1,570: Line 1,570:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
 
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
Line 1,578: Line 1,578:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Severe Mosquito Bite  Allergy||Disease||
 
|    Severe Mosquito Bite  Allergy||Disease||
Line 1,586: Line 1,586:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
 
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
Line 1,594: Line 1,594:  
|
 
|
 
|?PENDING
 
|?PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
 
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
Line 1,602: Line 1,602:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
 
|'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
Line 1,611: Line 1,611:  
|Complete
 
|Complete
 
|9/26/2022
 
|9/26/2022
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|     Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
Line 1,620: Line 1,620:  
|Complete
 
|Complete
 
|1/21/2021
 
|1/21/2021
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Monomorphic  Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
 
|     Monomorphic  Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
Line 1,629: Line 1,629:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Intestinal T-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|     Intestinal T-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
Line 1,638: Line 1,638:  
|Complete
 
|Complete
 
|9/26/2022
 
|9/26/2022
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Indolent T-cell  Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
 
|    Indolent T-cell  Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
Line 1,647: Line 1,647:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Hepatosplenic T-cell Lymphoma||Disease||Michelle Don
 
|Hepatosplenic T-cell Lymphoma||Disease||Michelle Don
Line 1,656: Line 1,656:  
|Complete
 
|Complete
 
|1/21/2021
 
|1/21/2021
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
 
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
Line 1,664: Line 1,664:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
 
|Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
Line 1,672: Line 1,672:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee)
 
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee)
Line 1,680: Line 1,680:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
 
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
Line 1,688: Line 1,688:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
 
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
Line 1,696: Line 1,696:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
 
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
Line 1,704: Line 1,704:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
 
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
Line 1,712: Line 1,712:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
 
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
Line 1,720: Line 1,720:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
 
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
Line 1,728: Line 1,728:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
 
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
Line 1,736: Line 1,736:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
 
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
Line 1,744: Line 1,744:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
−
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
+
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Bo Hong
−
|
   
|
 
|
 
|
 
|
−
| ||SP
   
|
 
|
 +
| ||SK
 
|
 
|
 +
|SP (prior AE); 2021 template added
 
|-
 
|-
 
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
 
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
Line 1,760: Line 1,760:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Angioimmunoblastic  T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 
|     Angioimmunoblastic  T-cell Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
Line 1,769: Line 1,769:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Follicular T-cell  Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
 
|    Follicular T-cell  Lymphoma||Disease||Ruthann Pfau, Sara Akhavanfard (trainee)
Line 1,778: Line 1,778:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
 
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
Line 1,786: Line 1,786:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
 
|Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
Line 1,795: Line 1,795:  
|Completed
 
|Completed
 
|09/23/2022
 
|09/23/2022
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara  / Miguel Gonzalez (trainee)
 
|Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara  / Miguel Gonzalez (trainee)
Line 1,804: Line 1,804:  
|Completed
 
|Completed
 
|09/23/2022
 
|09/23/2022
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
Line 1,813: Line 1,813:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SK
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
| || ||
 
| || ||
Line 2,144: Line 2,144:  
|Astrocystoma, IDH-Mutant
 
|Astrocystoma, IDH-Mutant
 
|Disease
 
|Disease
 +
|Meenakshi Mehrotra
 +
|6/25/2023
 
|
 
|
−
|
+
|PENDING
−
|
  −
|
   
|
 
|
 
|Laveniya Satgunaseelan (LS)
 
|Laveniya Satgunaseelan (LS)
Line 2,158: Line 2,158:  
|COMPLETE
 
|COMPLETE
 
|
 
|
−
|Laveniya Satgunaseelan (LS)
+
|LS
 
|
 
|
 
|2021 template added
 
|2021 template added
Line 2,167: Line 2,167:  
|PENDING
 
|PENDING
 
|
 
|
−
|Laveniya Satgunaseelan (LS)
+
|LS
−
|
   
|
 
|
 +
|Moved from "Glioblasoma, IDH-wildtype" to new page; 2021 template added
 
|-
 
|-
−
|Diffuse Astrocytoma, MYB- or MYBL1-Altered||Disease||
+
|Diffuse Astrocytoma, MYB- or MYBL1-Altered||Disease||Scott Smith
−
|
+
|6/27/2023
−
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added (page created 6/27/23)
 
|-
 
|-
 
|Angiocentric Glioma||Disease||
 
|Angiocentric Glioma||Disease||
Line 2,927: Line 2,927:  
|
 
|
 
|-
 
|-
−
|Anaplastic Large Cell Lymphoma (ALK+/ALK−)||Disease||
+
|Anaplastic Large Cell Lymphoma (ALK+/ALK−)||Disease||Jennie Thurston
−
|
+
|7/2/2023
−
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
 
|T-cell and NK/T-cell Lymphomas||Disease||
 
|T-cell and NK/T-cell Lymphomas||Disease||
Line 3,125: Line 3,125:  
|
 
|
 
|-
 
|-
−
|Constitutional Mismatch Repair Deficiency Syndrome||Disease||
+
|Constitutional Mismatch Repair Deficiency Syndrome||Disease||Jennie Thurston
−
|
+
|7/2/2023
−
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added; Named page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" based on GTS5 book name
 
|-
 
|-
 
|Familial Adenomatous Polyposis 1||Disease||
 
|Familial Adenomatous Polyposis 1||Disease||
Line 3,170: Line 3,170:  
|
 
|
 
|-
 
|-
−
|DICER1 Syndrome||Disease||
+
|DICER1 Syndrome||Disease||Jennie Thurston
−
|
+
|7/2/2023
−
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added; Name page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" based on GTS5 book name
 
|-
 
|-
 
|Familial Paraganglioma Syndromes||Disease||
 
|Familial Paraganglioma Syndromes||Disease||
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/11849...11882"